Bayer, a global leader in radiology and cardiology, has acquired two investigational cardiac amyloidosis imaging agents of Attralus, a clinical-stage biopharmaceutical company, in a major molecular imaging push.

 

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology.

 

“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President of Bayer’s Pharmaceuticals Division. 

 

“AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes – a clear extension of our commitment to tackling cardiovascular disease and addressing significant unmet needs.”

 

The acquired portfolio includes AT-01, a PET tracer in Phase III development, and AT-05, a SPECT tracer in Phase I, both targeting cardiac amyloidosis—a rare, often fatal heart disease affecting an estimated 400,000 people worldwide. Current diagnostic methods frequently fail to detect the condition early, delaying treatment and worsening patient outcomes.

 

“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level,” said Nelson Ambrogio, President Radiology at Bayer. 

 

“This acquisition marks our entry into diagnostic tracers. Leveraging our expertise in medical imaging – including our pipeline and portfolio in advanced fluid delivery devices for nuclear medicine – it supports our ambition to expand in the growing field of molecular imaging. Building on Attralus’ research and development expertise, we will further advance scientific progress with the aim to broaden diagnostic options and make a meaningful difference for people living with cardiac amyloidosis.”

 

The global market for radio-diagnostic tracers was valued at approximately $3 billion in 2024 and is expected to grow sharply in the coming years. With its extensive radiology portfolio, clinical development capabilities, and global commercial reach, Bayer is positioned to accelerate innovation and deliver integrated diagnostic solutions that improve patient outcomes.

 

“We are excited to finalize this agreement with Bayer, whose expertise and global footprint in radiology will help to accelerate the development and launch of AT-01 and AT-05, our two novel diagnostic imaging agents for systemic amyloidosis,” said Glen Firestone, President of Attralus. 

 

“Despite recent progress in systemic amyloidosis, most patients continue to remain undiagnosed or are diagnosed too late in their disease progression. Consistent with Attralus’ mission, we believe that these pan-amyloid imaging agents will enable earlier diagnosis and treatment, leading to improved patient outcomes. 

 

"Bayer’s commitment to scientific rigor and patient impact makes them well-suited to bring these agents to clinicians and patients worldwide. Attralus will now focus on advancing its innovative pan-amyloid removal therapeutics, with AT-02 in Phase II and next-generation candidates in preclinical development.”